Evidence map›Paper›PMID 40746899›Full record

ArticleOncology research2025

Rare Primary Diffuse Large B-Cell Lymphoma Confined to Bone Marrow: Features and Prognosis.

Weiwei Chen, Xiaodie Zhou, Huiyu Li, Yuchen Yang, Lu Lu, Chunyan Zhu, Rong Fang, Xiaoyuan Chu, Shuping Zhou, Qian Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weiwei ChenDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Xiaodie ZhouDepartment of Pathology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Huiyu LiDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Yuchen YangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Lu LuDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Chunyan ZhuDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Rong FangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Xiaoyuan ChuDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.
Shuping ZhouDepartment of Gastroenterology, First Affiliated Hospital, Anhui University of Science & Technology, Huainan, 235000, China.
Qian SunDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001-2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence ( Conclusion: Our findings highlight the aggressive nature of PBM-DLBCL and underscore the importance of early recognition, risk stratification, and optimized treatment selection for this rare disease entity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBone MarrowBone Marrow NeoplasmsLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRituximabTreatment OutcomeYoung AdultRituximabchemotherapydiffuse large B-cell lymphoma (DLBCL)Primary bone marrow lymphomas (PBMLs)prognosisrituximab

Identifiers

PMID40746899
PMCPMC12308260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.